VBL Therapeutics Reports Positive Top-line Interim Results From VB-111 Phase 2

(RTTNews) - VBL Therapeutics (VBLT) announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma, which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression.

Dror Harats, CEO, said: "We continue to work to bring VB-111 forward as a potential new treatment option, and look forward to initiating a pivotal Phase 3 trial in recurrent glioblastoma later this year."